India, Sept. 4 -- Cipla Ltd on Thursday announced that its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical to license and supply a biosimilar of the cancer drug Keytruda in the United States.
The product, QL2107, is a biosimilar of pembrolizumab (Keytruda) and is aimed at expanding access to advanced cancer treatments while helping reduce treatment costs, Cipla said in a regulatory filing.
Under the partnership, Qilu will oversee the product's development, regulatory registration and supply, while Cipla will use its commercial presence in the US to market the asset.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....